Mr. Heffernan is Co-Founder, President, & CEO of Collegium Pharmaceutical Inc.
Prior to this, Mr. Heffernan was Founder, President, & CEO of Onset Therapeutics Inc. Before this, Mr. Heffernan had held positions as Co-Founder, President, & CEO of Clinical Studies Ltd, and as President & CEO of PhyMatrix Inc.
Mr. Heffernan has a BS degree in Pharmacy from the University of Connecticut and is a registered pharmacist.
Mr. Heffernan is the chairman of Ocata Therapeutics Inc.
Mr. Heffernan is an independent board member.
Mette Kirstine Agger
Deputy chairman, independent
Ms. Agger has been a Board Member of Veloxis since April 2010. Ms. Agger is Managing Partner of Lundbeckfond Ventures, a company fully owned by the Lundbeck Foundation. She joined the company on September 1, 2009.
Prior to this, Ms. Agger was CEO of 7TM Pharma A/S, which she cofounded in late 2000, and from 1996 to 2000 she was part of the management team at NeuroSearch A/S, responsible for business development and licensing.
Ms. Agger has a Master of Science in Biology from Copenhagen University and an MBA from the Henley Business School, UK.
Ms. Agger is a board member of Klifo A/S, PsiOxus Therapeutics Ltd, Cydan LLC, scPharmaceuticals LLC, Thesan Pharamceuticals Inc, and Vtesse Pharma.
Ms. Agger is an independent board member.
Dr. Thomas Dyrberg, MD
Board member, independent
Dr. Dyrberg has been a Board Member of Veloxis since September 2003. He is a Senior Partner and has served at Novo Ventures, Novo A/S, a Danish firm that provides capital for life science companies, since December 2000.
Prior to joining Novo A/S, he served in various positions at Novo Nordisk A/S, a health care company specializing in the treatment of diabetes. Prior to that, he held research positions at the Hagedorn Research Institute, Gentofte, Denmark, and the Scripps Research Institute, La Jolla, California, US.
Dr. Dyrberg received both an MD and a DMSc degree from the University of Copenhagen.
Dr. Dyrberg is board member of Ophthotech Corp, Panoptica Inc, Theia Inc and Delenex Therapeutics AG.
Dr. Dyrberg is an independent board member.
Board member, independent
Mr. Götzsche has been a Board Member of Veloxis since April 2008. Mr. Götzsche is Executive Vice President and Chief Financial Officer at H. Lundbeck. He joined Lundbeck on September 1, 2007.
After finishing his education in 1991, he joined PricewaterhouseCoopers in Denmark. From 1998 through 2001, Mr. Götzsche was Sales Manager with the SAS Institute Inc. He became Director of Group Accounting and Reporting for Group 4 Falck A/S. Before joining Lundbeck, Mr. Götzsche held the post of Chief Financial Officer for the Berlingske Officin A/S from 2005.
Mr. Götzsche holds an MS degree in Accounting from the University of Southern Denmark and became a state-authorized public accountant in 1997.
Mr. Götzsche is a board member of Rosborg Møbler A/S.